Resultats de la cerca - Agnès Guerci

Refinar resultats
  1. 1
    Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

    Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes per Mikkael A. Sekeres, Hagop M. Kantarjian, Pierre Fenaux, Pamela S. Becker, Adam Boruchov, Agnès Guerci‐Bresler, Kuolung Hu, Janet Franklin, Yow‐Ming Wang, Dietmar Berger

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study

    Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study per Norbert Vey, André Bosly, Agnès Guerci, Walter Feremans, Hervé Dombret, F. Dreyfus, David Bowen, Alan K. Burnett, Mike Dennis, Vincent Ribrag, Nicole Casadevall, Laurence Legros, Pierre Fenaux

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

    Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation per Jean‐Claude Chomel, Marie Laure Bonnet, Nathalie Sorel, Ivan Sloma, Annelise Bennaceur‐Griscelli, Delphine Réa, Laurence Legros, Anne Marfaing‐Koka, Jean Bourhis, Shanti Amé, Agnès Guerci‐Bresler, Philippe Rousselot, Ali G. Turhan

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

    Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome per Marc Berger, Bruno Pereira, Philippe Rousselot, Pascale Cony‐Makhoul, Martine Gardembas, Laurence Legros, Martine Escoffre‐Barbe, Franck‐Emmanuel Nicolini, Sandrine Saugues, Céline Lambert, Delphine Réa, Agnès Guerci‐Bresler, Stéphane Giraudier, Joëlle Guilhot, Susanne Saußele, François‐Xavier Mahon

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group

    Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group per Cécile Bally, Jehane Fadlallah, Guy Leverger, Yves Bertrand, Alain Robert, André Baruchel, Agnès Guerci, Christian Récher, Emmanuel Raffoux, Xavier Thomas, Thierry Leblanc, Nadia Idres, Bruno Cassinat, Norbert Vey, Christine Chomienne, Hervé Dombret, Miguel Á. Sanz, Pierre Fenaux, Lionel Adès

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia

    Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia per Laurence Legros, Franck E. Nicolini, Gabriel Étienne, Philippe Rousselot, Delphine Réa, Stéphane Giraudier, Agnès Guerci‐Bresler, Françoise Huguet, Martine Gardembas, Martine Escoffre, Jean‐Christophe Ianotto, Marie‐Pierre Noël, Bruno Varet, Thomas Pagliardini, Isabelle Touitou, Stéphane Morisset, François‐Xavier Mahon

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

    Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group per Lionel Adès, Sylvie Chevret, Emmanuel Raffoux, Stéphane de Botton, Agnès Guerci, Arnaud Pigneux, Anne Marie Stoppa, T. Lamy, Françoise Rigal‐Huguet, Anne Vekhoff, Sandrine Meyer‐Monard, Frédéric Maloisel, Éric Deconinck, Augustin Ferrant, Xavier Thomas, Nathalie Fegueux, Christine Chomienne, Hervé Dombret, Laurent Degos, Pierre Fenaux

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome

    Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome per Mariane de Montalembert, Jean-Antoine Ribeil, Valentine Brousse, Agnès Guerci‐Bresler, Aspasia Stamatoullas, Jean-Pierre Vannier, C. Dumesnil, Agnès Lahary, Mohamed Touati, Krimo Bouabdallah, Marina Cavazzana, Emmanuelle Chauzit, Amandine Baptiste, Thibaud Lefèbvre, Hervé Puy, Caroline Elie, Zoubida Karim, Olivier Ernst, Christian Rosé

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

    Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study per Maël Heiblig, Delphine Réa, Marie‐Lorraine Chrétien, Aude Charbonnier, Philippe Rousselot, Valérie Coiteux, Martine Escoffre‐Barbe, Viviane Dubruille, Françoise Huguet, Émilie Cayssials, Éric Hermet, Agnès Guerci‐Bresler, Shanti Amé, Lucila Sackmann‐Sala, Lydia Roy, Mohamad Sobh, Stéphane Morisset, Gabriel Étienne, Franck E. Nicolini

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

    Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Franc... per Adès, Lionel, Le Bras, Fabien, Sebert, Marie, Kelaidi, Charikleia, Lamy, Thierry, Dreyfus, François, Eclache, Virginie, Delaunay, Jacques, Bouscary, Didier, Visanica, Sorin, Turlure, Pascal, Bresler, Agnès Guerci, Cabrol, Marie-Paule, Banos, Anne, Blanc, Michel, Vey, Norbert, Delmer, Alain, Wattel, Eric, Chevret, Sylvie, Fenaux, Pierre

    Publicat 2012
    Obtenir text complet Obtenir text complet Obtenir text complet
    Text
    Afegir a favorits
    Guardat en:
  11. 11
    Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

    Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group per Adès, Lionel, Thomas, Xavier, Bresler, Agnes Guerci, Raffoux, Emmanuel, Spertini, Olivier, Vey, Norbert, Marchand, Tony, Récher, Christian, Pigneux, Arnaud, Girault, Stephane, Deconinck, Eric, Gardin, Claude, Tournilhac, Olivier, Lambert, Jean Francois, Chevallier, Patrice, de Botton, Stephane, Lejeune, Julie, Dombret, Hervé, Chevret, Sylvie, Fenaux, Pierre

    Publicat 2018
    Obtenir text complet Obtenir text complet Obtenir text complet
    Text
    Afegir a favorits
    Guardat en:
  12. 12
    Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

    Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up... per Jorge E. Cortés, Hagop M. Kantarjian, Delphine Réa, Meir Wetzler, Jeffrey H. Lipton, Luke P. Akard, H. Jean Khoury, Mauricette Michallet, Agnès Guerci‐Bresler, Charles Chuah, Andrzej Hellmann, Raghunadharao Digumarti, Purvish M. Parikh, Laurence Legros, Krzysztof Warzocha, Michele Baccarani, Elizabeth Li, Mihaela Munteanu, Franck E. Nicolini

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations

    Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations per Sarah Ducamp, Caroline Kannengiesser, Mohamed Touati, Loïc Garçon, Agnès Guerci‐Bresler, Jean François Guichard, Christiane Vermylen, Joaquim Dochir, Hélène A. Poirel, Fanny Fouyssac, L Mansuy, Geneviève Leroux, G. Tertian, Robert Girot, H. Heimpel, Thomas Matthes, Neila Talbi, Jean‐Charles Deybach, Carole Beaumont, Hervé Puy, Bernard Grandchamp

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia

    Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia per François Guilhot, Claude Chastang, Mauricette Michallet, Agnès Guerci, Jean‐Luc Harousseau, Frédéric Maloisel, Réda Bouabdallah, Denis Guyotat, Nathalie Cheron, Franck E. Nicolini, Jean‐François Abgrall, J Tanzer, Maurice Navarro, Dominique Bordessoule, Patrick Morice, Norbert Ifrah, H Rochant, Jean‐Pierre Vilque, Martine Delain, F Bauters, Joëlle Guilhot

    Publicat 1997
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

    Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study per Delphine Réa, Guylaine Henry, Zena Khaznadar, Gabriel Étienne, François Guilhot, Franck E. Nicolini, Joëlle Guilhot, Philippe Rousselot, Françoise Huguet, Laurence Legros, Martine Gardembas, Viviane Dubruille, Agnès Guerci‐Bresler, Aude Charbonnier, Frédéric Maloisel, Jean‐Christophe Ianotto, Bruno Villemagne, François‐Xavier Mahon, Hélène Moins‐Teisserenc, Nicolas Dulphy, Antoine Toubert

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

    Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study per Delphine Réa, Franck E. Nicolini, Michel Tulliez, François Guilhot, Joëlle Guilhot, Agnès Guerci‐Bresler, Martine Gardembas, Valérie Coiteux, Gaëlle Guillerm, Laurence Legros, Gabriel Étienne, Jean‐Michel Pignon, Bruno Villemagne, Martine Escoffre‐Barbe, Jean‐Christophe Ianotto, Aude Charbonnier, Hyacinthe Johnson‐Ansah, Marie‐Pierre Noël, Philippe Rousselot, François‐Xavier Mahon

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group per Delphine Réa, Shanti Amé, Marc Berger, Jean‐Michel Cayuela, Aude Charbonnier, Valérie Coiteux, Pascale Cony‐Makhoul, Viviane Dubruille, Stéphanie Dulucq, Gabriel Étienne, Laurence Legros, Franck E. Nicolini, Catherine Roche‐Lestienne, Martine Escoffre‐Barbe, Martine Gardembas, Agnès Guerci‐Bresler, Hyacinthe Johnson‐Ansah, Françoise Rigal‐Huguet, Philippe Rousselot, François‐Xavier Mahon

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

    Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia per Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini, Agnès Guerci‐Bresler, Françoise Rigal‐Huguet, Frédéric Maloisel, Valérie Coiteux, Martine Gardembas, Christian Berthou, Anne Vekhoff, Delphine Réa, Éric Jourdan, Christian Allard, Alain Delmer, Philippe Rousselot, Laurence Legros, Marc Berger, Sélim Corm, Gabriel Étienne, Catherine Roche‐Lestienne, Virginie Éclache, François‐Xavier Mahon, François Guilhot

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

    Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? per Valeria Santini, Jennifer Schemenau, Alessandro Levis, Enrico Balleari, Rosa Sapena, Lionel Adès, Agnès Guerci, Odile Beyne‐Rauzy, Marie‐Pierre Gourin, Stéphane Chèze, Aspasia Stamatoullas, Alessandro Sanna, Daniela Gioia, Gianni Cametti, Dario Ferrero, Emmanuel Raffoux, Christian Rosé, Antonella Poloni, Thomas Prébet, Laurence Legros, Shanti Natarajan‐Amé, Pierre Fenaux, Ulrich Germing, François Dreyfus, Sophie Park

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

    Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib... per Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul, Philippe Agapé, Franck E. Nicolini, Bruno Varet, Martine Gardembas, Gabriel Étienne, Delphine Réa, Lydia Roy, Martine Escoffre‐Barbe, Agnès Guerci‐Bresler, Michel Tulliez, Stéphane Prost, Marc Spentchian, Jean Michel Cayuela, Josy Reiffers, Jean‐Claude Chomel, Ali G. Turhan, Joëlle Guilhot, François Guilhot, François‐Xavier Mahon

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: